Mechanism of DCs Dysfunction in Chronic HBV Infection
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 132
- 试验地点
- 1
- 主要终点
- Define the subversion mechanism of dendritic cells (DCs) by hepatitis B virus (HBV)
研究概览
简要总结
This research is to better understand the functional impairments of Dendritic cells (DCs) in chronic HBV infection. Aim is to determine if the virus is able to bind to the C-type lectin receptor (CLRs) of DCs to modulate their functions, also, to define the role of viral components and the molecular mechanisms of DCs modulation by HBV. This project should provide a better understanding of the mechanisms by which the immune response is altered by HBV and the immunological control of the infection, and thus propose new immunotherapeutic strategies based on the restoration of DC functions by releasing of virally-induced inhibitions, compromising the infection chronicity
详细描述
Currently, chronic hepatitis B virus (HBV) infection therapies are limited to pegylated interferon alpha (Peg-IFNα) and nucleos(t)ide analogues (NUCs), alone or in combination. Even though they can reduce viremia level (circulating viral load), the loss of HBs antigen (HBsAg), which indicates functional clearance of the virus, is achieved in less than 10% of cases.
The absence of curative treatment to eliminate the infection justifies the need to define new targets and to develop new therapeutic strategies, with an immuno-therapeutic component.
Chronic HBV infection is associated with persistent and virally-induced immune deficiency. The immunological control of the infection seems essential to the functional clearance of the virus. The restoration of appropriate immune responses against the virus could prove to be a promising therapeutic strategy. However, the mechanisms in which HBV modulates immune function is still poorly understood.
Dendritic cells (DCs) have an essential role in immunity. They play a central role in the induction and regulation of immune responses. Also, they play a particularly crucial role in the induction and orientation of antiviral immunity due to their unique properties at the interface between innate and acquired immune responses. In several chronic viral infections, DCs appear defective. The immune responses induced in the early stages of infection seem to be a crucial guide on the progression of the infection into the resolution or the chronicity.
Objective of the investigators is to better understand the virus escape mechanism from immune control, particularly, to determine the mechanisms in which the virus modulates the functions of DCs, crucial for the subsequent orientation of antiviral immune responses, to define the molecular mechanisms of this inhibition and their consequences on the antiviral effectors functions, in order to propose new immunotherapeutic approaches that compromise the chronicity of the infection and treat the infection permanently and definitively.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- •For groups 1a, 1b and 2 (HBV or NASH patients):
- •Positive serology for HCV, HDV, HTLV, HIV
- •Active autoimmune diseases
- •Immunosuppressive therapies
- •Cancer <2 years
- •Alcohol: male> 30g / day, female> 20g / day
- •Group 1a and 1b:
- •NASH patients
- •Positive HBsAg Group 3: Blood samples from healthy donors
- •Positive serology for HCV, HTLV, HIV, HBV (in the sense of a positive HBsAg test).
- •Risk of any infectious disease at the time of sample collection (including fever> 38 ° C over the past 15 days or recent contact with a person with a contagious disease).
- •Autoimmune disease or immunosuppressive therapy at the time of sample collection.
结局指标
主要结局
Define the subversion mechanism of dendritic cells (DCs) by hepatitis B virus (HBV)
时间窗: 4 years
Differential expression of the tested molecules (DCIR, dectin 1, DEC205, DC-SIGN, Clec12a, CD206, CD207, Clec9a, CD32) on circulating and hepatic mDCs (BDCA1+ et BDCA3+) of HBV patients compared to controls (healthy donors for circulating DCs, or NASH patients for hepatic DCs)
次要结局
- Demonstrate the correlations between immunological and clinical parameters(4 years)
